Skip to main content

Table 1 Comparative intrinsic activity: Range (mg/l) of MIC50 and MIC90 from published studies

From: Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults

 

References

Amoxicillin/clavulanic acid

Cefuroxime

Cefditoren

MIC50

MIC90

MIC50

MIC90

MIC50

MIC90

Streptococcus pyogenes a

13–15

≤0.012–0.06

≤0.012–0.12

0.03–0.06

0.12

≤0.03

≤0.03–0.06

Streptococcus pneumoniae b

14,15,41–48

      

 Penicillin-susceptible

 

≤0.015–0.06

0.03–0.25

≤0.03

0.12–0.25

≤0.015

≤0.03–0.06

 Penicillin-intermediate

 

0.25–1

1–4

0.5–4

4–8

0.06–0.25

0.25–0.5

 Penicillin-resistant

 

2 - ≥16

8 - ≥16

4–8

8–32

0.25–0.5

0.5–1

Haemophilus influenzae

 β-lactamase negative

14,15,22,41,44

0.25–1

1–8

0.25–2

1–8

≤0.08

≤0.03–0.06

 β-lactamase positive

14,15,22,41,44

0.5–2

2–4

1–2

2–8

≤0.08

≤0.03–0.06

 BLNAR

14,15,65

2

4

0.5–4

2–16

≤0.08

0.03–0.06

 BLPACR

65

4

8

4

16

0.03

0.06

Moraxella catarrhalis (β-lactamase positive)

14,15,22,23

0.12–0.5

0.25–2

1

2–8

0.06–0.12

0.25–0.5

  1. aIn terms of ampicillin (ref. [13])
  2. bIn terms of amoxicillin (ref. [14, 15, 43,44,45,46])